EUVIMEDEUVIMED entdecken
Crossref

Impact of IgG Fc Glycosylation on Disease Dynamics in Patients With Primary Sjögren Disease

Helena Achten iD, Leander Meuris, Liselotte Deroo iD, Matthias Jarlborg, Tine Decruy, Joke Deprez, Emilie Dumas, Kristel De Boeck, Eva Genbrugge, Wouter Bauters, Frederick Dochy, David Creytens und 4 weitere

Arthritis & Rheumatology · 2025

DOI: 10.1002/art.43018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Helena Achten und 15 weiteren Autor:innen. Beteiligte Einrichtung: Ghent University Hospital and Gent University, Ghent, Belgium, and VIB-UGent Inflammation Research Center, Zwijnaarde, Belgium. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Immunoglobulin G, Immunoglobulin Fc Fragments. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Fund for Scientific Research on Rheumatology, Research Foundation - Flanders.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Glycans attached to the Fc region of IgG antibodies influence their pro‐ or anti‐inflammatory effector function. We aimed to explore the interrelation of the Fc glycosylation profile and disease transition, disease activity, and outcome in patients with suspected and confirmed primary Sjögren disease (SjD).

Methods

IgG Fc sialylation and IgG Fc galactosylation serum levels were determined in 300 patients from the Belgian Sjögren's Syndrome Transition Trial. This cohort includes both suspected and confirmed patients with SjD meeting the 2016 American College of Rheumatology/EULAR criteria. Salivary gland involvement was evaluated through ultrasonography (Hocevar score 0–48) and histopathology (focus score). The relative amount of sialylated and galactosylated IgG was determined by capillary electrophoresis after using the endoglycosidase S‐based assay.

Results

Patients with SjD exhibited significantly lower sialylation and galactosylation levels versus asymptomatic carriers of anti‐SSA and patients with sicca. Lower sialylation and galactosylation levels were significantly associated with an increase in B cell activation markers and distinct autoantibody profiles, particularly with multiple autoantibody reactivities. They were also linked to histopathological salivary gland alterations, higher Hocevar scores, and, importantly, risk factors for non‐Hodgkin lymphoma (NHL) development. In contrast, patients with SjD who were mono‐anti‐Ro60 positive and those who were anti‐SSA negative had normal IgG Fc glycosylation.

Conclusion

This study points to a novel role of IgG Fc glycosylation in patients with SjD in predicting disease transition, monitoring disease activity, and stratifying risk of NHL development. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sjogren's SyndromeImmunoglobulin GImmunoglobulin Fc FragmentsHumansFemaleMiddle AgedGlycosylationMaleSalivary GlandsAdultAgedAutoantibodiesDisease ProgressionGlycoproteins

Substanzen

Immunoglobulin GImmunoglobulin Fc Fragmentsglycosylated IgGAutoantibodiesGlycoproteins

Autor:innen und Institutionen

  • Ghent University Hospital and Gent University, Ghent, Belgium, and VIB-UGent Inflammation Research Center, Zwijnaarde, Belgium.
  • VIB-UGent Center for Medical Biotechnology, Ghent, Belgium.
  • Ghent University Hospital and Gent University, Ghent, Belgium.
  • VIB-UGent Inflammation Research Center, Zwijnaarde, Belgium.
  • Ghent University Hospital, Ghent, Belgium.
  • Ghent University Hospital and Gent University, Ghent, Belgium, VIB-UGent Inflammation Research Center, Zwijnaarde, Belgium, and AZ Sint-Jan Brugge AV, Bruges, Belgium.

ORCID-Profile: Helena Achten, Liselotte Deroo, Dirk Elewaut, Isabelle Peene

Förderung

  • Fund for Scientific Research on Rheumatology
  • Research Foundation - Flanders

Zitieren

APA

Achten, H., Meuris, L., Deroo, L., Jarlborg, M., Decruy, T., Deprez, J., Dumas, E., De Boeck, K., Genbrugge, E., Bauters, W., Dochy, F., Creytens, D., Roels, D., Callewaert, N., Elewaut, D., & Peene, I. (2025). Impact of IgG Fc Glycosylation on Disease Dynamics in Patients With Primary Sjögren Disease. Arthritis & Rheumatology. https://doi.org/10.1002/art.43018

Vancouver

Achten H, Meuris L, Deroo L, Jarlborg M, Decruy T, Deprez J, et al. Impact of IgG Fc Glycosylation on Disease Dynamics in Patients With Primary Sjögren Disease. Arthritis & Rheumatology. 2025. doi:10.1002/art.43018

BibTeX
@article{Achten2025,
  author = {Achten, Helena and Meuris, Leander and Deroo, Liselotte and Jarlborg, Matthias and Decruy, Tine and Deprez, Joke and Dumas, Emilie and De Boeck, Kristel and Genbrugge, Eva and Bauters, Wouter and Dochy, Frederick and Creytens, David and Roels, Dimitri and Callewaert, Nico and Elewaut, Dirk and Peene, Isabelle},
  title = {Impact of IgG Fc Glycosylation on Disease Dynamics in Patients With Primary Sjögren Disease},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  doi = {10.1002/art.43018}
}
Kostenlos starten →